Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.

Authors :: Carrasco MA
Source :: Cornea [Cornea] 2008 Jul; Vol. 27 (6), pp. 743-5.
Publication Year :: 2008
Abstract: Purpose: To report an 81-year-old woman with corneal neovascularization secondary to herpetic stromal keratitis treated with subconjunctival bevacizumab and to discuss the role of this novel antiangiogenic treatment.<br />Methods: Case report and review of medical literature.<br />Results: A dramatic regression of corneal vessels was observed 1 week after the injection. After a 3-month follow-up, there was no recurrence of corneal revascularization.<br />Conclusions: Bevacizumab may be a valid complementary treatment in patients with corneal neovascularization caused by herpetic stromal keratitis.

Subjects :: Acyclovir therapeutic use
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Bevacizumab
Corneal Neovascularization etiology
Corneal Stroma virology
Female
Humans
Keratitis, Herpetic drug therapy
Treatment Outcome
Vascular Endothelial Growth Factor A antagonists & inhibitors
Angiogenesis Inhibitors therapeutic use
Antibodies, Monoclonal therapeutic use
Corneal Neovascularization drug therapy
Keratitis, Herpetic complications

Full Text Access

Tools